# Safety, Tolerability and Pharmacokinetics of Cobimetinib in Combination With Pictilisib in Patients With Locally Advanced or Metastatic Solid Tumors

> **NCT00996892** · PHASE1 · TERMINATED · sponsor: **Genentech, Inc.** · enrollment: 178 (actual)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** Cobimetinib
- **DRUG:** Pictilisib

## Key facts

- **NCT ID:** NCT00996892
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-11
- **Primary completion:** 2014-03
- **Final completion:** 2014-03
- **Target enrollment:** 178 (ACTUAL)
- **Why stopped:** A recommended Phase 2 dose and schedule was not identified and the study was terminated before initiation of Stage 2B.
- **Last updated:** 2016-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00996892

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00996892, "Safety, Tolerability and Pharmacokinetics of Cobimetinib in Combination With Pictilisib in Patients With Locally Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT00996892. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*